Dacarbazine citrate | CAS# 64038-56-8 | anticancer drug

MedKoo Cat#: 581192 | Name: Dacarbazine citrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dacarbazine citrate belongs to the group of medicines called alkylating agents. It is used to treat cancer of the lymph system and malignant melanoma (a type of skin cancer). It may also be used to treat other kinds of cancer, Dacarbazine citrate interferes with the growth of cancer cells, which are eventually destroyed. Dacarbazine citrate is used in certain patients with the following medical conditions: Cancer of the islet cells (a part of the pancreas) Soft tissue sarcomas (a cancer of the muscles, tendons, vessels that carry blood or lymph, joints, and fat).

Chemical Structure

Dacarbazine citrate

CAS#64038-56-8 (citrate)

Theoretical Analysis

MedKoo Cat#: 581192

Name: Dacarbazine citrate

CAS#: 64038-56-8 (citrate)

Chemical Formula: C12H18N6O8

Exact Mass: 0.0000

Molecular Weight: 374.31

Elemental Analysis: C, 38.51; H, 4.85; N, 22.45; O, 34.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

4342-03-4 (free base) 17925-90-5 (HCl) 64038-56-8 (citrate)

Synonym

Dacarbazine citrate; Dacarbazine citrate; DTIC citrate; UNII-9UYU348NIF;

IUPAC/Chemical Name

Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-, citrate

InChi Key

UKLSKIDEWQXQJZ-ASTDGNLGSA-N

InChi Code

InChI=1S/C6H10N6O.C6H8O7/c1-12(2)11-10-6-4(5(7)13)8-3-9-6;7-3(8)1-6(13,5(11)12)2-4(9)10/h3H,1-2H3,(H2,7,13)(H,8,9);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b11-10+;

SMILES Code

O=C(C1=C(/N=N/N(C)C)NC=N1)N.OC(C(O)=O)(CC(O)=O)CC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 374.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Di Martino A, Sedlarik V. Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy. Int J Pharm. 2014 Oct 20;474(1-2):134-45. doi: 10.1016/j.ijpharm.2014.08.014. Epub 2014 Aug 12. PubMed PMID: 25124059. 2: Stark P, Steinmetz A, Hefetz M, Hardoff R. Misleading Ga-67 uptake in a patient with Hodgkin's disease, mediastinal deviation, and pulmonary compression. Clin Nucl Med. 2002 Dec;27(12):898-9. PubMed PMID: 12607876. 3: St-Coeur PD, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P Jr. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics. J Neurooncol. 2015 Oct;125(1):91-102. doi: 10.1007/s11060-015-1899-6. Epub 2015 Aug 28. PubMed PMID: 26311249. 4: Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Lacave AJ. Phase I trial of intermittent high-dose dacarbazine. Cancer Treat Rep. 1984 Mar;68(3):499-504. PubMed PMID: 6704980. 5: Lunn G, Sansone EB. Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid. Am J Hosp Pharm. 1987 Nov;44(11):2519-24. PubMed PMID: 3687991. 6: Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg. 1992 Jan;28(1):60-4. PubMed PMID: 1642408. 7: Ha CS, Choe JG, Kong JS, Allen PK, Oh YK, Cox JD, Edmund E. Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome. Cancer. 2000 Sep 15;89(6):1371-9. PubMed PMID: 11002233. 8: Re A, Ferrari S, Frata P, Pizzocaro C, Crippa C, Tucci A, Facchetti F, Grazioli L, Magrini SM, Rossi G. Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. Ann Oncol. 2008 May;19(5):951-7. doi: 10.1093/annonc/mdm596. Epub 2008 Jan 21. PubMed PMID: 18209012. 9: Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg. 1992 Jan;28(1):65-9. PubMed PMID: 1642409. 10: Saita C, Yajima K, Iwasaki Y, Oohinata R, Ishiyama S, Yuu K. [Multidisciplinary Treatment for a Patient with Primary Malignant Melanoma Arising from the Stomach]. Gan To Kagaku Ryoho. 2015 Jul;42(7):859-61. Japanese. PubMed PMID: 26197750. 11: Fukunaga T, Soejima H, Sugamura K, Kojima S, Sugiyama S, Sakamoto T, Yoshimura M, Tanoue T, Kageshita T, Ono T, Ogawa H. Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report. J Cardiol. 2006 Apr;47(4):191-5. PubMed PMID: 16637253. 12: Herman K, Szabó L, Leopold LF, Chiş V, Leopold N. In situ laser-induced photochemical silver substrate synthesis and sequential SERS detection in a flow cell. Anal Bioanal Chem. 2011 May;400(3):815-20. doi: 10.1007/s00216-011-4798-5. Epub 2011 Feb 26. PubMed PMID: 21359570. 13: Zinzani PL, Zompatori M, Bendandi M, Battista G, Fanti S, Barbieri E, Gherlinzoni F, Rimondi MR, Frezza G, Pisi P, Merla E, Gozzetti A, Canini R, Monetti N, Babini L, Tura S. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1996 Jun;22(1-2):131-5. PubMed PMID: 8724540. 14: Liang P, Shi H, Zhu W, Gui Q, Xu Y, Meng J, Guo X, Gong Z, Chen H. Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells. Oncotarget. 2017 Jan 31;8(5):7533-7539. doi: 10.18632/oncotarget.13503. PubMed PMID: 27893419; PubMed Central PMCID: PMC5352340.